You are on the new improved site. You can view the old site in view-only mode here until June 27, 2026

Filter Results

Search all journals

Enter search terms…

Advanced search

/

About

About Sage
About Sage Journals
Privacy Policy
Terms of Use
Contact Us
Help

Information for

Authors
Editors
Librarians
Researchers
Reviewers
Frequently asked questions

Copyright © 2026 by Sage Publications.京ICP备09090397号-11

Search results

Search results page

Articles (32)

Journals (0)

1-10 of 32 results for gastric or gastroesophageal junction adenocarcinoma

Sort by:

Relevance

Select all

Select all

Sort by:

Relevance

Select article: Comparing treatment and outcomes in advanced esophageal,gastroesophageal junction,and gastric adenocarcinomas: a population-based study

Open access

Research article

First published 2023

Comparing treatment and outcomes in advanced esophageal,gastroesophageal junction,and gastric adenocarcinomas: a population-based study

Marieke Pape, Pauline A. J. Vissers, Willemieke P. M. Dijksterhuis [...]

Therapeutic Advances in Medical Oncology

Select article: Cost-effectiveness of cadonilimab plus chemotherapy in the first-line treatment of HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma

Open access

Research article

First published 2025

Cost-effectiveness of cadonilimab plus chemotherapy in the first-line treatment of HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma

Shixian Liu, Kaixuan Wang, Ruixue Wang [...]

Therapeutic Advances in Gastroenterology

Select article: First-line treatment with zolbetuximab plus CAPOX for ClDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a cost-effectiveness analysis

Open access

Research article

First published 2024

First-line treatment with zolbetuximab plus CAPOX for ClDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a cost-effectiveness analysis

Jianying Lei, Jiahao Zhang, Caicong You [...]

Therapeutic Advances in Gastroenterology

Select article: Symptom Burden and Healthcare Resource Use in Patients With Claudin 18.2–Positive,HER2-Negative,Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: A Retrospective Review

Open access

Research article

First published 2026

Symptom Burden and Healthcare Resource Use in Patients With Claudin 18.2–Positive,HER2-Negative,Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: A Retrospective Review

Matheus Sewastjanow-Silva, Mok Oh, Lawrence Chang [...]

Clinical Medicine Insights: Oncology

Select article: Cost-effectiveness of sequential treatment strategies involving first-line pembrolizumab with trastuzumab and chemotherapy for unresectable metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma

Open access

Research article

First published 2025

Cost-effectiveness of sequential treatment strategies involving first-line pembrolizumab with trastuzumab and chemotherapy for unresectable metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma

Caicong You, Jiahao Zhang, Jianying Lei [...]

Therapeutic Advances in Medical Oncology

Select article: Camrelizumab plus SOX chemotherapy as adjuvant therapy for pathological stage III gastric or gastroesophageal junction adenocarcinoma: a prospective,multicenter,single-arm,phase II trial

Open access

Research article

First published 2025

Camrelizumab plus SOX chemotherapy as adjuvant therapy for pathological stage III gastric or gastroesophageal junction adenocarcinoma: a prospective,multicenter,single-arm,phase II trial

Hailong Jin, Jiren Yu, Yuan Gao [...]

Therapeutic Advances in Medical Oncology

Select article: First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric cancer,gastroesophageal junction cancer,and esophageal adenocarcinoma: a cost-effectiveness analysis

Open access

Research article

First published 2023

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric cancer,gastroesophageal junction cancer,and esophageal adenocarcinoma: a cost-effectiveness analysis

Xueqiong Cao, Mingming Zhang, Na Li [...]

Therapeutic Advances in Medical Oncology

Select article: Optimizing treatment duration with ramucirumab and paclitaxel by managing chemotherapy-associated toxicity: Review of four cases

Open access

Case report

First published 2020

Optimizing treatment duration with ramucirumab and paclitaxel by managing chemotherapy-associated toxicity: Review of four cases

Man Yee Merl, Renee Moye, Anindya Chatterjee [...]

Sage Open Medical Case Reports

Select article: Real-World Outcomes and Factors Associated With the Second-Line Treatment of Patients With Gastric,Gastroesophageal Junction,or Esophageal Adenocarcinoma

Open access

Research article

First published 2019-1

Real-World Outcomes and Factors Associated With the Second-Line Treatment of Patients With Gastric,Gastroesophageal Junction,or Esophageal Adenocarcinoma

Afsaneh Barzi, Lisa M. Hess, Yajun E. Zhu [...]

Cancer Control

Select article: Cadonilimab plus chemotherapy for patients with HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma in China and the United States: a cost-effectiveness analysis

Open access

Research article

First published 2026

Cadonilimab plus chemotherapy for patients with HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma in China and the United States: a cost-effectiveness analysis

Jia Wang, Baolong Ding, Zhuying Jing [...]

Therapeutic Advances in Medical Oncology

1
2
3
4
10 / page

Article type

Publication date

Subjects

Access